Intelligence Report · ~12 min read

Teva Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 21, 2026

Confidence

Moderate Confidence · 81%

Evidence

12 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Teva maintains an active intelligence profile across Neurology, Multiple System Atrophy, Dermatology, Vitiligo. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 81% across 2 tracked sources. Highest-priority development: FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG). Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Teva.

Key Developments

Material intelligence events ranked by strategic relevance.

regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — POMALIDOMIDE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — POMALIDOMIDE (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — AJOVY (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 44 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — POMALIDOMIDE (SUPPL)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (ORIG)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — POMALIDOMIDE (SUPPL)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — AJOVY (SUPPL)
Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

Teva's TEV-56286 Trial for Multiple System Atrophy Underway
Neurology · Multiple System Atrophy
Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy
Dermatology · Vitiligo

Executive Summary

Key Developments

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

FDA AP — POMALIDOMIDE (SUPPL)

FDA AP — BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (ORIG)

FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)

FDA AP — POMALIDOMIDE (SUPPL)

FDA AP — AJOVY (SUPPL)

Strategic Implications

Supporting Evidence

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

FDA AP — POMALIDOMIDE (SUPPL)

FDA AP — BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (ORIG)

FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)

FDA AP — POMALIDOMIDE (SUPPL)

FDA AP — AJOVY (SUPPL)

Related Intelligence

Signals